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Abstract
Background: Sequential physicochemical alterations in blood and urine in the course of acute kidney injury (AKI)
development have not been previously described. We aimed to describe these alterations in parallel to traditional
renal and acid–base parameters.
Methods: One hundred and sixty eight consecutive critically ill patients with no previous kidney disease, who had
an indwelling urinary catheter at ICU admission and who remained with the catheter for at least two days without
dialysis were included. A sample of blood and spot urine were collected simultaneously, once daily, until catheter
removal or dialysis requirement. Traditional acid–base and renal parameters were sequentially evaluated in parallel
to blood and urinary physicochemical parameters. Patients were classified during this period as having or not AKI and,
for patients with AKI, duration (transient or persistent) and severity (creatinine-based AKIN stage) were evaluated.
Results: One hundred and thirteen patients (67.3%) had AKI: 92 at ICU admission and 21 during the observation period.
AKI development was characterized in blood by increased values of phosphate and unmeasured anions (SIG), decreased
albumin, and in urine by decreased values of sodium (NaU), chloride (ClU) as well as high urinary strong ion difference
(SIDu). These alterations began to occur before AKI diagnosis, and they reverted in transient AKI but remained in
persistent AKI. NaU, ClU and albumin decreased, and phosphate, SIG and SIDu increased with AKI severity progression.
NaU and ClU values increased again when AKIN stage 3 was reached.
Conclusions: Simultaneous physicochemical analysis of blood and urine revealed standardized alterations that
characterize AKI development in critically ill patients. These alterations paralleled AKI duration and severity. Future studies
should consider including sequential evaluation of urine biochemistry as part of the armamentarium for AKI diagnosis
and management.
Keywords: Urine biochemistry, Urine electrolytes, Physicochemical analysis, Stewart approach, Acute kidney injury,
Strong ion gap, Strong ion difference, Critically ill patients
Background
Blood and urinary indices are frequently used to distin-
guish a transient, reversible decline in kidney function,
from a persistent, structural kidney impairment (generally
attributed to acute tubular necrosis (ATN)). However, dis-
crimination based on these indices has been questioned
[1-3] with no evidence of ATN in most cases [4,5]. The
correlation between structural kidney damage and urinary
biochemistry is also frequently questioned [1,6]. Few stud-
ies have evaluated the accuracy of urinary indices in
distinguishing transient and persistent acute kidney injury
(AKI), with conflicting results [7-10].
Nowadays, urinary biochemical analysis is considered
of little use in the diagnosis and management of AKI, es-
pecially in sepsis [11-13]. However, preliminary results
of our group showed that sequential analysis of some
urinary biochemical parameters has a potential role in
detect AKI even before increases in creatinine [14,15]. In
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addition, a physicochemical acid–base analysis of blood
[16] and urine [17,18] has also been previously used to
describe some of the alterations that occur when renal
function is impaired. However, these studies were lim-
ited to patients with established AKI: none has focused
on a sequential evaluation of these physicochemical
parameters in the course of AKI, including the days
preceding AKI diagnosis.
The aims of the present study were to describe the se-
quential analysis of blood and urinary physicochemical
parameters in critically ill patients according to AKI
duration (transient or persistent) and AKI severity.
Methods
The “Hospital das Clínicas da Faculdade de Medicina da
Universidade de São Paulo” ethics committee approved
the study (protocol number 0093/11), and the need for
informed written consent was waived by the same com-
mittee. The study was conducted prospectively in a sin-
gle, mixed medical-surgical 6-bed ICU from October
2009 to November 2011. Blood laboratory exams used in
this study were all collected routinely, once daily, between
8 p.m. and 10 p.m., from every patient in our ICU. These
exams include arterial blood gases, arterial lactate, serum
urea, creatinine (SCr), Na+, K+, Ca2+, Mg2+, Cl-, phosphate
and albumin. In addition, starting in October 2009, we in-
cluded a spot urine sample as part of the routine exams.
Urine sample was only taken from patients with a urinary
catheter in place when blood was being collected. We
measured Na+ (NaU), K+ (KU), Cl- (ClU), urea (UrU) and
creatinine (CrU) levels in the spot urine sample, and a 2-h
creatinine clearance was calculated using the 8 p.m. to
10 p.m. urine volume (the collection bag is emptied every
2 hours in our ICU). Urinary strong ion difference (SIDu),
standard base excess (SBE), apparent strong ion difference
(SIDa), effective strong ion difference (SIDe), strong ion
gap (SIG), fractional excretion of sodium (FENa) and urea
(FEUr) were calculated daily using the exams previously
mentioned (see formulas below). For the purposes of this
study, we analyzed consecutive patients who had a urin-
ary catheter inserted before or at ICU admission and
remained with the catheter for at least the first two days
of routine exams in the ICU. We excluded patients who
were discharged, died, had the urinary catheter removed
or needed dialysis before completing these two sets of
routine exams. Patients with kidney transplant, chronic
renal failure, or who were readmitted to the ICU were
also excluded. The observation period for each patient
begins at ICU admission until indwelling urinary catheter
removal (minimum of two days) or need for renal re-
placement therapy, which of the two that occurred first.
Urinary catheter insertion and removal was at the discre-
tion of the assistant physician and not influenced by the
ongoing study.
Patients demographics, associated comorbidities, se-
verity scores (SAPS 3 [19] and SOFA[20]), urine output
and fluid balance, use of vasopressors, bicarbonate and
loop diuretics, need for mechanical ventilation and renal
replacement therapy during the observation period as
well as ICU and hospital mortality were recorded.
Physicochemical approach to acid–base disturbances
In the Stewart approach [21], modified by Figge [22], the
difference between strong (completely dissociated) cat-
ions and anions (SID), and Atot (the total concentration
of the weak acids albumin and phosphate) are the de-
terminants of the metabolic acid–base profile. To keep
electroneutrality of the solution, water molecules dissociate
when there is a decrease in SID; the resulted increment in
the concentration of free protons decreases pH (an acidify-
ing effect).
In physiological conditions, the difference between strong
cations and anions (SIDa) is equal to the sum of bicarbon-
ate and the dissociated part of weak acids (SIDe). In the
presence of unmeasured anions, SIDa is greater than SIDe
and this difference is called strong ion gap (SIG).
The kidneys are the major regulators of plasma SID.
Normally functioning kidneys are able to counteract in-
creases in circulating acids by increasing the net acid ex-
cretion in urine. The main mechanism for urinary acid
excretion is an increase in urinary ammonium (NH4
+), the
combination of ammonia (NH3), a metabolite of glutamine,
and a proton (H+). Urinary NH4
+ is usually not directly
measured but inferred by the urinary strong ion difference
(SIDu): NaU + KU – ClU. To keep electroneutrality, in-
creases in urinary NH4
+ are usually accompanied by in-
creases in urinary Cl- concentration, decreasing the SIDu.
We calculated standard base excess (SBE), SIDa, SIDe,
SIG, SIDu, fractional excretion of sodium (FENa) and
urea (FEUr) using standard formulas:
1. SBE (Van Slyke equation) (mEq/L) = 0.9287 ×
(HCO3
- (mmol/L) – 24.4 + 14.83 × [pH – 7.4])
2. Apparent strong ion difference (SIDa) (mEq/L) =Na+
(mEq/L) + K+ (mEq/L) + Ca2+ (mEq/L) + Mg2+
(mEq/L) – [Cl- (mEq/L) + lactate- (mEq/L)]
3. Effective strong ion difference (SIDe) (mEq/L) = 2.46 ×
10-8 × PCO2/10
-pH + [(10 × albumin (g/dL)) × (0.123 ×
pH – 0.631)] + [(phosphate (mg/dL) × 10/30.97) ×
(0.309 × pH – 0.469)]
4. SIG (mEq/L) = SIDa – SIDe
5. FENa (%) = [(NaU(mEq/L)/Na+ (mEq/L))/(CrU
(mg/dL)/SCr (mg/dL))] × 100
6. FEUr (%) = [(UrU (mg/dL)/urea (mg/dL))/(CrU
(mg/dL)/SCr (mg/dL))] × 100
7. 2-h creatinine clearance (ml/min) = [(CrU (mg/dL) ×
(8 p.m. to 10p.m.diuresis volume (ml)))/SCr
(mg/dL)]/120
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Acute kidney injury diagnosis and reversal
We defined acute kidney injury (AKI) based on the AKIN
[23] creatinine criteria considering the time period during
which the patient was with a urinary catheter. Baseline
serum creatinine (baseSCr) was defined as the lowest SCr
in the previous 3 months before ICU admission. Measured
SCr was adjusted daily for cumulative fluid balance [24].
We used the lowest value between baseSCr and adjusted
creatinine in the first 7 days of the study to determine if
the patient had AKI at admission. To diagnose AKI during
ICU stay we used the lowest SCr in the last 48 hours (refer-
ence creatinine (refSCr)). AKINmax refers to the worst
AKIN stage reached during the study period.
Transient AKI was determined when SCr returned to
a value lower than (SCr used for diagnosis + 0.3 mg/dL)
or (SCr used for diagnosis × 1.5) within 48 hours of on-
set, depending on which of the two criteria made the
diagnosis. Day 0 (D0) refers to the day in which AKI
diagnosis was made or, for patients who did not develop
AKI, the first ICU day. Days −1 (D-1) and −2 (D-2) refer
respectively to 24 and 48 h before the AKI diagnosis,
and days 1 (D1) and 2 (D2) refer respectively to 24 and
48 h after the AKI diagnosis or after ICU admission (for
no-AKI patients). If the patient did not continue with
the urinary catheter for 48 hours after AKI diagnosis,
the creatinine values of those two days were retrospect-
ively retrieved in order to define AKI reversal.
Laboratory techniques and measurements
All samples were analyzed in the central laboratory of
our institution. Serum Na+, K+, Ca2+ and Cl- concen-
trations were measured using the direct ion-selective
electrode technique; Mg2+ was measured using a col-
orimetric technique; phosphate was measured using an
ultraviolet technique. Urea was measured with a kinetic
technique both in blood and urine, and albumin was
measured with a bromocresol dye colorimetric tech-
nique. NaU, KU and ClU were also measured using the
direct ion-selective electrode technique, while creatin-
ine was measured in both blood and urine using a kinetic
colorimetric technique. Arterial blood gas was analyzed,
and lactate was measured on the OMNI analyzer (Roche
Diagnostics System, F. Hoffmann-La Roche Ltd, Basel,
Switzerland).
Statistical analyses
Continuous variables were expressed as median and
25–75 percentiles and categorical variables were expressed
as absolute (n) and relative (%) frequency. Between-
group differences for continuous variables were analyzed
by the non-parametric Wilcoxon–Mann–Whitney test.
Categorical variables were analyzed by Pearson’s χ2-
test or Fisher’s exact test, whenever appropriate. All
statistical tests were two-sided and p < 0.05 was consid-
ered significant. Statistical analyses were conducted using
SPSS 19.0 (Chicago, Illinois).
Results
Incidence of transient and persistent AKI
A hundred and sixty eight patients were included in this
analysis. During the study period 113 patients (67.3%)
had AKI: 92 (81.4%) at ICU admission and 21 (18.6%)
during ICU stay. Fifty out of the 92 patients (54.3%) with
AKI at admission had a transient AKI and 42 (45.7%)
Figure 1 Flowchart of patients included in the analysis according to AKI duration.
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had a persistent AKI. Seven out of 21 patients (33.3%)
with AKI diagnosed during ICU stay had a transient AKI
and 14 (66.7%) had a persistent AKI (Figure 1).
Epidemiologic differences between transient
and persistent AKI
General characteristics of the patients in the 3 groups
are shown in Table 1. No differences were found in age,
gender, ideal body weight and associated chronic organ
failures between groups. Patients who developed persist-
ent AKI had higher SAPS 3 and SOFA score at admis-
sion. BaseSCr was significantly lower in the no-AKI
patients. No differences between groups were found
in the percentage of patients who had used diuretics or
needed mechanical ventilation. However, bicarbonate and
vasopressor use was more prevalent in patients who devel-
oped persistent AKI. Only one patient in the transient AKI
group required renal replacement therapy but long after
complete recovery from the first transient episode of AKI.
AKIN stages 2 or 3 were significantly more prevalent in
persistent AKI than in transient AKI. Both ICU and hos-
pital mortality were also significantly higher in patients
with persistent AKI.
Traditional renal and acid–base parameters in the course
of AKI
Most AKI diagnosis were made at ICU admission, thus
only a few patients had the values recorded 2 days before
Table 1 Main characteristics of patients according to acute kidney injury (AKI) status during the observation period
No AKI (n = 55) Transient AKI (n = 57) Persistent AKI (n = 56) P
Male gender 30 (54.5%) 31 (54.4%) 32 (57.1%) 0.95
Age (years) 47 [29,63] 54 [38,62] 56 [45,69] 0.19
Ideal body weight (Kg) 56 [52,63] 54 [48,64] 55 [48,63] 0.79
SAPS 3 (ICU admission) 33 [27,50] 47 [37,57] 51 [33,62] 0.01
SOFA (ICU admission) 4 [2,7] 6 [4,8] 7 [5,10] 0.01
Associated diseases
-COPD 1 (1.8%) 1 (1.8%) 1 (1.8%) 1.00
-Heart failure 4 (7.3%) 5 (8.8%) 10 (17.9%) 0.16
-Cirrhosis 3 (5.5%) 1 (1.8%) 0 (0%) 0.16
Creatinine baseline- mg/dl 0.63 [0.51,0.79] 0.91 [0.63,1.17] 0.84 [0.64,1.08] <0.01
Loop Diuretics 17 (30.9%) 27 (47.4%) 26 (46.4%) 0.14
Bicarbonate 4 (7.3%) 9 (15.8%) 17 (30.4%) 0.01
Vasopressor 14 (25.5%) 25 (43.9%) 35 (62.5%) <0.01
Mechanical ventilation 33 (60%) 35 (61.4%) 36 (64.3%) 0.89
Renal replacement therapy 0 (0%) 1 (1.8%) 17 (30.4%) <0.01
Main diagnosis 0.01
-Severe sepsis/septic shock 8 (14.5%) 17 (29.8%) 29 (51.7%)
-Respiratory failure 10 (18.2%) 12 (21.1%) 9 (16.0%)
-Neurologic syndromes 9 (16.4%) 8 (14.0%) 6 (10.8%)
-Post-operative 7 (12.7%) 7 (12.3%) 2 (3.6%)
-Trauma 8 (14.5%) 3 (5.3%) 1 (1.8%)
-Non-septic shock 2 (3.7%) 4 (7.0%) 2 (3.6%)
-Others 11 (20%) 6 (10.5%) 7 (12.5%)
Maximum AKIN stage <0.01
-Stage 1 37 (64.9%) 11 (19.7%)
-Stage 2 15 (26.3%) 25 (44.6%)
-Stage 3 5 (8.8%) 20 (35.7%)
Mortality
-ICU 3 (5.5%) 7 (12.3%) 17 (30.4%) 0.01
-Hospital 7 (12.7%) 11 (19.3%) 25 (44.6%) <0.01
SAPS: simplified acute physiology score; SOFA: sequential organ failure assessment; ICU: intensive care unit;
COPD: chronic obstructive pulmonary disease; AKIN: acute kidney injury network.
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AKI diagnosis (n = 13). A low 2 h-creatinine clearance was
already observed two days before AKI diagnosis (Table 2).
Creatinine values were significantly higher in persistent
AKI compared to transient AKI at the day of AKI diagnosis
(D0). Transient AKI patients still had higher creatinine
levels than no-AKI patients at D2. Although not statisti-
cally significant, measured 2 h-creatinine clearance was
also still lower in transient AKI compared to no-AKI
patients at D2. Urea levels paralleled creatinine levels on
all days and within all groups. 24 h-urine output and fluid
balance were similar between groups on all days. No statis-
tical differences were found in SBE and bicarbonate levels
between groups at D0, but persistent AKI patients had a
slightly lower SBE at D2. Median PCO2 was significantly
lower in persistent AKI in comparison to transient AKI at
D1 and D2. Median pH levels were in normal range on all
Table 2 Traditional renal and acid–base parameters in the course of acute kidney injury (AKI)
Day −2 (n = 13) Day −1 (n = 21) Day 0 (n = 168) Day +1 (n = 164) Day +2 (n = 117)
Urea (mg/dL) No-AKI - - 27 [21,46] 29 [20,48] 27 [19,45]
transient 37 [34,40] 45 [40,68] 68 [51,90] 63 [42,89] 48 [34,66]
persistent 33 [20,42] 47 [35,65] 75 [60,115] 84 [62,136] 95 [58,132]
P *0.00/ **0.30/ ***0.00 0.00/ 0.00/ 0.00 0.00/ 0.00/ 0.00
Creatinine (mg/dL) No-AKI - - 0.68 [0.55,0.82] 0.69 [0.57,0.83] 0.62 [0.54,0.76]
transient 0.66 [0.60,0.73] 0.79 [0.63,0.94] 1.24 [0.86,1.70] 0.98 [0.81,1.45] 0.82 [0.65,1.09]
persistent 0.72 [0.58,0.80] 0.91 [0.59,1.02] 1.62 [1.17,2.55] 1.73 [1.11-2.48] 1.69 [1.07,2.38]
P 0.00/ 0.02/ 0.00 0.00/ 0.00/ 0.00 0.00/ 0.00/ 0.02
24 h-urine output (mL/kg/h) No-AKI - - 1.13 [0.68,1.88] 1.13 [0.81,2.24] 1.39 [0.80,1.93]
transient 1.74 [1.40,2.15] 0.65 [0.42,1.04] 1.18 [0.79,1.95] 1.36 [0.92,2.31] 1.07 [0.68,2.08]
persistent 1.31 [0.94,2.00] 0.87 [0.60,1.67] 0.83 [0.62,1.28] 0.97 [0.48,1.42] 0.93 [0.55,1.34]
P 0.28/ 0.11/ 0.72 0.12/ 0.07/ 0.79 0.18/ 1.00/ 0.49
24 h-fluid balance (mL) No-AKI - - 408 [−492,973] 220 [−419,765] 160 [−655,685]
transient 514 [171,1130] 890 [85,968] −119 [−770,891] −260 [−754,455] −64 [−1082,1190]
persistent 841 [174,1001] 691 [30,1515] 158 [−255,922] 255 [−391,717] 27 [−697,807]
P 0.18/0.10/ 0.08 0.10/0.05/ 0.14 0.71/0.78/ 0.76
pH No-AKI - - 7.38 [7.33,7.42] 7.39 [7.36,7.41] 7.39 [7.37,7.42]
transient 7.38 [7.38,7.38] 7.39 [7.31,7.43] 7.36 [7.32,7.40] 7.39 [7.35,7.41] 7.40 [7.37,7.43]
persistent 7.42 [7.38,7.48] 7.41 [7.33,7.44] 7.35 [7.30,7.40] 7.38 [7.35,7.41] 7.39 [7.36,7.42]
P 0.04/ 0.51/ 0.26 0.32/ 0.38/ 1.00 0.80/ 0.43/ 0.73
PCO2 (mmHg) No-AKI - - 41 [34,47] 40 [35,46] 40 [35,45]
transient 40 [38,51] 45 [35,53] 41 [33,46] 41 [35,46] 42 [37,48]
persistent 39 [32,42] 38 [33,44] 37 [33,43] 37 [31,43] 37 [33,44]
P 0.29/ 0.25/0.71 0.00/ 0.00/ 0.90 0.05/ 0.02/ 0.38
SBE (mEq/L) No-AKI - - −2.6 [−3.7,1.1] −0.9 [−3.3,1.6] 0.2 [−2.5,2.3]
transient 1.5 [−1.1,2.0] −0.4 [−3.4,0.7] −2.6 [−6.2,0.2] −1.1 [−3.8,2.6] 1.2 [−2.1,4.6]
persistent 0.7 [−2.7,2.6] 0.2 [−5.6,1.7] −4.1 [−7.4,-0.4] −3.2 [−6.6,-0.4] −1.9 [−3.4,0.4]
P 0.24/ 0.07/ 0.85 0.04/ 0.10/ 0.70 0.01/ 0.01/ 0.20
Bicarbonate (mEq/l) No-AKI - - 22.4 [20.8,25.8] 23.7 [21.4,26.6] 24.5 [22.2,26.7]
transient 26.9 [22.3,27.9] 23.4 [22.3,26.7] 22.1 [18.7,25.3] 23.6 [20.6,27.2] 25.4 [22.2,29.3]
persistent 24.4 [21.9,26.3] 24 [19.1,26.4] 20.3 [17.5,24.5] 21.5 [17.6,24.7] 22.9 [20.5,25.3]
P 0.07/ 0.07 / 0.85 0.027/ 0.042/ 0.847 0.00/ 0.01/ 0.20
2 h-creatinine clearance(mL/min) No-AKI - - 117.8 [55.9,180.0] 111.7 [92.0,194.0] 112.7 [63.9,228.1]
transient 57.7 [18.7-234.6] 56.9 [13.4,202.8] 66.5 [41.5,115.9] 85.2 [51.6,194.7] 76.0 [41.1,148.1]
persistent 59.7 [32.2-114.5] 25.9 [9.0,72.5] 31.7 [19.0,49.5] 29.7 [14.1,58.3] 36.8 [15.2,69.0]
P 0.00/ 0.00/ 0.03 0.00/ 0.00/ 0.24 0.01/ 0.35/ 0.36
Day 0: day of AKI diagnosis; SBE: standard base excess; * among the three groups; ** between transient and persistent AKI; *** between no AKI and transient AKI.
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days of observation in all groups but significantly different
between groups at D0 (lower in persistent AKI).
Blood physicochemical parameters in the course of AKI
Median SIDa was stable and similar in no-AKI, transient
and persistent AKI patients on all days (Table 3). SIDe
was lower in persistent AKI and reached significant dif-
ference between groups at D2. Both SIG and phosphate
levels were higher in AKI patients at D0, decreasing to
values similar to no-AKI patients at D2 in the transi-
ent group and remaining high in the persistent group
(Table 3, Figure 2 – panel A). At D0, albumin values
were also different between groups, the lowest values
found in the persistent AKI group. At D1, albumin was sig-
nificantly lower in persistent AKI in comparison to transi-
ent AKI (Table 3).
Urinary physicochemical parameters in the course of AKI
Spot urinary electrolytes
NaU, KU, ClU, NaU/KU ratio and SIDu were also evalu-
ated from D-2 to D2 (Table 4). At D0, both NaU and
ClU were significantly different between groups, with
the lowest values in persistent AKI (Table 4, Figure 2 –
panel B). This difference between groups remained until
D2. NaU/KU ratio was also different between groups
reaching statistical significance at D1 and D2 (lowest values
in persistent AKI). AKI development was characterized in
both AKI groups by decreases in NaU and ClU values as
well as in NaU/KU ratio on the 2 days preceding AKI diag-
nosis. In transient AKI, decreases in NaU, ClU and NaU/
KU ratio were also transient (Table 4, Figure 2- panel B); in
persistent AKI, their values remained low. This pattern
was not altered by diuretic use during the observation
period (Additional file 1: Figure S1). No differences
were found in the KU values between and within groups.
SIDu had a transitory increase in transient AKI but a
sustained increase in persistent AKI. At D2, patients with
persistent AKI had a significantly higher SIDu than pa-
tients with a transient AKI (Table 4, Figure 2- panel B).
Fractional excretion of electrolytes
No significant differences were found in FENa and FEUr
between or within groups on all days (Table 4). This pat-
tern was similar in patients who had and had not used
diuretics in the observation period (Additional file 2:
Figure S2).
Blood and urinary physicochemical parameters and AKI
severity
To evaluate if variations in blood and urinary physico-
chemical parameters were proportional to the degree of
AKI severity, we compared these parameters among
Table 3 Blood physicochemical parameters in the course of acute kidney injury (AKI)
Day −2 (n = 13) Day −1 (n = 21) Day 0 (n = 168) Day +1 (n = 164) Day +2 (n = 117)
SIDa (mEq/L) No-AKI - - 39.2 [35.7,42.7] 39.3 [35.9,42.9] 40.1 [37.4,43.9]
transient 35.8 [33.7,39.8] 39.9 [37.1,41.6] 39.6 [36.0,42.7] 39.2 [36.2,43.4] 39.5 [37.0,43.3]
persistent 39.5 [37.1,44.6] 40.2 [38.4,47.4] 38.5 [35.9,40.7] 38.8 [36.5,42.6] 39.7 [37.6,44.6]
P *0.75/**0.45/*** 0.63 0.96/ 0.77/ 0.92 0.89/ 0.90/ 0.90
SIDe (mEq/L) No-AKI - - 32.9 [29.7,37.4] 33.7 [30.9,37.4] 34.6 [32.1,38.3]
transient 35.5 [31.1,36.9] 32.2 [30.2,34.7] 33.0 [28.3,36.3] 34.7 [30.6,37.2] 35.9 [30.9,40.0]
persistent 34.1 [31.8,37.1] 33.8 [29.3,38.2] 29.8 [27.4,35.0] 31.0 [26.8,34.7] 32.4 [29.7,35.3]
P 0.07/ 0.07/ 0.85 0.12/ 0.04/ 0.38 0.03/ 0.03/ 0.73
SIG (mEq/L) No-AKI - - 4.8 [2.9,7.3] 4.8 [3.3,6.4] 5.2 [4.1,7.1]
transient 4.6 [3.0,4,9] 6.5 [5.7,8.2] 5.9 [4.1,7.3] 5.1 [3.5,7.1] 4.3 [2.0,6.6]
persistent 6.3 [4.0,7.7] 7.9 [5.0,9.1] 7.1 [4.7,9.7] 8.7 [5.8,10.8] 7.6 [5.2,10.3]
P 0.01/ 0.26/ 0.22 0.00/ 0.00/ 0.33 0.01/ 0.00/ 0.12
Phosphate– (mEq/L) No-AKI - - 1.9 [1.3,2.3] 1.4 [1.2,1.9] 1.4 [1.1,1.9]
transient 1.6 [1.5,2.0] 1.7 [1.4,2.0] 2.2 [1.6,2.8] 1.7 [1.3,2.0] 1.3 [1.1,2.0]
persistent 1.4 [1.3,1.5] 2.1 [1.3,2.5] 2.4 [1.7,3.1] 2.2 [1.6,2.8] 2.2 [1.6,2.7]
P 0.02/ 0.22/ 0.06 0.00/ 0.01/ 0.12 0.00/ 0.00/ 0.55
Albumin– (mEq/l) No-AKI - - 8.8 [6.8,9.8] 8.0 [6.6,9.3] 8.3 [6.9,9.4]
transient 5.8 [5.3,6.4] 5.6 [5.2,6.4] 8.0 [7.1,9.0] 7.9 [6.8,9.2] 7.8 [6.9,9.0]
persistent 8.3 [7.5,8.9] 7.9 [7.1,8.8] 7.1 [6.2,8.3] 7.0 [6.2,7.9] 7.0 [6.5,8.1]
P 0.01/0.07/ 0.19 0.00/ 0.02/ 0.50 0.14/ 0.22/ 0.55
Day 0: day of AKI diagnosis; SIDa: apparent strong ion difference; SIDe: effective strong ion difference; SIG: strong ion gap (=SIDa-SIDe).
* among the three groups; ** between transient and persistent AKI; *** between no-AKI and transient AKI.
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patients who reached AKINmax stage 1, 2 or 3 during the
observation period (Figure 3). We compared the values of
these parameters on the day that AKINmax was reached
for each patient; patients with no-AKI served as controls,
with ICU values at admission used for comparison. Of 113
patients with AKI, 48 (42.5%) had an AKINmax stage 1, 40
(35.4%) stage 2 and 25 (22.1%) stage 3 (Table 1). Both SIG
and phosphate increased, and albumin decreased with AKI
severity progression (Figure 3A). Both NaU and ClU values
decreased with progression of AKI severity except when
AKINmax stage 3 was reached (Figure 3B). SIDu increased
until stage 2 but decreased in stage 3 (Figure 3B). Median
values of FENa were low (< 1%) in no-AKI and AKINmax
stages 1 and 2 but high values were observed in AKINmax
stage 3 (Figure 3C). Median FEUr values had only slight
variations across AKINmax stages (Figure 3D). Median
urine output (ml/kg/h) was not different across AKINmax
stages (1.13, 1.12, 0.97, 0.99 respectively).
Discussion
Urinary and blood indices have long been used as tools
to distinguish functional and structural AKI [25,26].
However, the relevance of these indices is questioned by
many, mainly because their values are widely variable,
influenced by medications (diuretics [8], aminoglycosides
[27], contrast [28]), concomitant diseases (cirrhosis [29],
sepsis [30], rabdomiolysis [31]) and with a significant dis-
sociation from renal histopathological findings [6]. How-
ever, most previous studies in this area were small and
with a non-sequential evaluation of these parameters [11].
In our study, we demonstrated that there is a standard
behavior of some parameters during AKI development: de-
creases in NaU and ClU, and increases in SIG, phosphate
and SIDu. Since AKI duration is relevant to prognosis
(a finding confirmed by our results), we have also demon-
strated that transient AKI (creatinine elevation for less
than 48 hours) is followed by equally transient alter-
ations in these parameters both in blood and urine
(Tables 3 and 4, Figure 2). Persistent AKI, on the other
hand, was characterized by persistent alterations in these
parameters or, at least, by a slower recovery.
Increases in SIG and phosphate are the main sources
of metabolic acidosis in AKI, usually counterbalanced by
hypoalbuminemia [16]. Notably, in our study, SIG and
phosphate levels were significantly but only modestly in-
creased in AKI patients in comparison to no-AKI patients
Figure 2 Summary of the main blood and urinary physicochemical parameters between 2 days before (-2) until 2 days after (2) acute
kidney injury (AKI) diagnosis (0), according to AKI duration. Panel A. Blood parameters. Panel B. Urinary parameters. SIG: strong ion gap;
P: phosphorus; NaU: urinary sodium; ClU: urinary chloride; SIDu: urinary strong ion difference.
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(Table 3). It is noteworthy that no-AKI patients had
an increased SIG (around 5 mEq/L) probably related
to critical illness itself. In AKI patients, additional
modest increases in SIG (2–3 mEq/L) and phosphate
(0.5-1 mEq/L) may be signs of incipient renal dysfunc-
tion. In addition, the majority of our AKI patients were
not acidemic nor had very low levels of SBE. Possible
explanations for this were (a) low levels of albumin in
AKI patients, counterbalancing the increased acid load
of SIG and phosphate, and (b) greater bicarbonate use
in AKI patients, although it was used in the minority of
the patients (Table 1), even in persistent AKI. Hence,
metabolic acidosis with acidemia is expected to be
present only in advanced AKI or in the presence of
other concomitant sources of metabolic acidosis, such as
tissue hypoperfusion, which is likely to be present specially
in persistent AKI due to the high prevalence of vasopressor
use in this group.
We have also shown that, in parallel to the blood
acid–base and physicochemical alterations that follow
AKI development, some relevant alterations also occur
in urine composition (Table 4), even in the presence of
acceptable urine outputs (Table 2). Since some of these
urinary alterations (decreases in NaU, ClU and NaU/KU
ratio, and increases in SIDu) seem to precede increases
in creatinine, they may aid in early AKI diagnosis. De-
creases in NaU and ClU were previously considered part
of so-called “pre-renal” AKI. Spot NaU values lower than
20 mEq/L were classically considered one of the major
markers of functional AKI [25]; values above 40 mEq/L
were indicative of structural AKI impairment mainly due
to ATN. This paradigm, however, has been criticized by
Table 4 Urinary physicochemical parameters in the course of acute kidney injury (AKI)
Day −2 (n = 13) Day −1 (n = 21) Day 0 (n = 168) Day +1 (n = 164) Day +2 (n = 117)
NaU (mEq/L) No-AKI - - 89 [44,167] 101 [51,143] 137 [95,195]
transient 146 [79,175] 52 [31,127] 54 [22,90] 62 [30,123] 115 [72,180]
persistent 134 [39,175] 116 [48,164] 41 [18,84] 45 [22,88] 58 [23,109]
P *0.00/ **0.09/ ***0.00 0.06/ 0.44/ 0.15 0.00/ 0.01/ 0.55
ClU (mEq/L) No-AKI - - 113 [39,173] 109 [52,163] 125 [95,184]
transient 130 [113,187] 43 [39,170] 56 [23,101] 68 [31,135] 135 [80,191]
persistent 124 [53,177] 126 [47,155] 39 [17,84] 42 [15,97] 60 [22,103]
P 0.00/ 0.12/ 0.00 0.00/ 0.21/ 0.07 0.00/ 0.00/ 0.48
KU (mEq/L) No-AKI - - 45 [31,70] 40 [29,53] 33 [23,46]
transient 49 [39,52] 52 [17,88] 36 [25,59] 38 [26,55] 36 [26,48]
persistent 37 [20,54] 41 [30,63] 48 [29,65] 42 [30,64] 37 [24,64]
P 0.54/ 0.34/ 0.34 0.61/ 0.34/ 0.50 0.51/ 0.55/ 0.43
NaU/KU ratio No-AKI - - 2.0 [0.7,3.8] 2.6 [0.7,4.2] 4.6 [2.1,7.9]
transient 2.9 [2.8,3.0] 1.2 [0.5,5.5] 1.2 [0.5,2.8] 1.4 [0.5,3.7] 4.2 [1.8,6.0]
persistent 4.5 [1.5,6.0] 2.1 [1.2,4.9] 0.8 [0.4,2.6] 1.2 [0.3,2.7] 1.4 [0.4,3.2]
P 0.17/ 0.34/ 0.18 0.01/ 0.44/ 0.07 0.00/ 0.09/ 0.55
SIDu (mEq/L) No-AKI - - 32 [15,88] 31 [−9,63] 29 [−2,67]
transient 21 [−5,71] 82 [9,107] 39 [16,58] 31 [1,57] 15 [−9,47]
persistent 29 [7,64] 41 [31,71] 48 [26,67] 45 [29,68] 39 [28,64]
P 0.21/ 0.44/ 0.44 0.16/ 0.12/ 0.92 0.00/ 0.00/ 0.22
FENa (%) No-AKI - - 0.5 [0.2,1.3] 0.5 [0.2,0.9] 1.0 [0.3,2.0]
transient 0.6 [0.3,2.0] 0.5 [0.3,0.6] 0.6 [0.2,1.3] 0.5 [0.2,1.2] 1.0 [0.3,1.7]
persistent 1.2 [0.3,4.8] 1.5 [0.4,2.4] 0.7 [0.2,1.7] 0.9 [0.2,2.3] 0.7 [0.3,3.5]
P 0.16/ 0.34/ 0.57 0.34/ 0.25/ 0.92 0.47/ 0.43/ 0.81
FEUr (%) No-AKI - - 32.1 [23.0,42.4] 35.7 [25.8,43.4] 35.8 [27.1,44.3]
transient 38.6 [17.4,49.2] 23.1 [19.7,40.0] 26.5 [16.7,42.6] 34.1 [26.2,44.0] 36.2 [26.9,49.8]
persistent 40.2 [30.6,48.8] 23.9 [21.2,43.2] 29.2 [19.8,36.8] 33.3 [21.8,43.6] 32.4 [24.9,43.8]
P 0.25/ 0.56/ 0.21 0.77/ 0.92/ 0.70 0.11/ 0.10/ 0.81
Day 0: day of AKI diagnosis; NaU: spot urinary sodium; ClU: spot urinary chloride; KU: spot urinary potassium; SIDu: spot urinary strong ion difference;
FENa: fractional excretion of sodium; FEUr: fractional excretion of urea.
* among the three groups; ** between transient and persistent AKI; *** between no-AKI and transient AKI.
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many authors [1,2,32], especially in sepsis [2]. Our data
suggest that progressive decreases in NaU and ClU
values may be viewed as part of AKI development in
critically ill patients. Increases in AKI severity were also
accompanied by more significant decreases in NaU and
ClU values. The exceptions were patients who have
reached AKIN stage 3 (Figure 3), in which increased
values of NaU and FENa might suggest a global tubular
dysfunction not present in less severe cases of AKI. In
AKIN stages 1 and 2, urinary alterations were more
compatible with a predominantly glomerular impairment
in the presence of preserved tubular function (at least in
the distal tubules). These findings do not imply that
there was no tubular injury in less severe forms of AKI.
Tubular injury as an early event in AKI has been dem-
onstrated previously by many studies using blood and
urinary biomarkers, even in those AKI previously consid-
ered “pre-renal” [33,34]. However, studies using urinary
microscopy [35,36] or biomarkers [33] simultaneously with
urinary biochemistry (to demonstrate tubular injury) have
found FENa < 1% in the majority of the patients, suggesting
a dissociation between tubular injury and function. Low
NaU/KU ratios and low FENa (Table 4) may be signs of
preserved mechanisms of renal adaptation to hemo-
dynamic insults, in which avid Na+ retention is followed
by K+ secretion in the distal tubules. In fact, neurohor-
monal mechanisms, including renin-angiotensin-aldoster-
one system activation, seem to be major characteristics of
AKI [37]. Nejat et al. [33] speculated that tubular injury is
a heterogeneous process in that residual normally func-
tioning nephrons may mask or compensate for others
already disabled. Our results suggest that global tubular
function is only clearly compromised in very severe and
advanced AKI stages, in which oliguria or very significant
elevations in SCr levels make the AKI diagnosis easy but
late. This “U” shape behavior of NaU in AKI progression,
with higher values both in no-AKI and in AKIN stage 3,
is one possible reason why isolated values of NaU are
difficult to interpret. However, a very low NaU value
should prompt an evaluation of factors that may stress
kidney function. In addition, we observed that very high
NaU values (above its normal plasma range) were rarely
found in AKI patients in our study (Table 4). Median
urine output was similar among different AKINmax
stages; it is possible that diuretics contributed to this
similar urine volume at the day that different AKINmax
stages were reached. This finding highlights the need to
access not only urine volume but sodium and chloride
content in the urine.
FEUr has been suggested as a more precise parameter
during diuretic use [7] and useful as a diagnostic index in
AKI [9]. Its value, however, was similar between groups in
our study, even when only patients who have used di-
uretics were evaluated (Additional file 2: Figure S2). This
result is in agreement with two previous studies that also
did not find utility in FEUr to discern transient and per-
sistent AKI [8,10]. High SIDu values may suggest an in-
ability of the injured kidneys to properly acidify urine (less
ammonium excretion), and this was characteristic of AKI
in our study (Table 4, Figure 3B). Previous studies [17,18]
also suggest that SIDu measurement may alert for the
presence of an impaired renal function in the presence of
metabolic acidosis. Negative SIDu values, although infre-
quent, seem to be restricted to patients without AKI or
with resolved AKI in our study (Table 4).
The high incidence of AKI in our study (67.3%), espe-
cially at admission, highlights the problem in consider-
ing admission creatinine as the baseSCr: many cases of
AKI are potentially not recognized. A similar high AKI
percentage was also found in a recent multicenter study in
Figure 3 Blood and urinary physicochemical parameters at the day of maximum AKIN stage of acute kidney injury (AKI)
(AKINmax). Panel A. Blood parameters: Phosphorus (P), Albumin and Strong ion gap (SIG). Panel B. Urinary sodium (NaU), chloride (ClU)
and strong ion difference (SIDu) Panel C. Fractional excretion of sodium (FENa) Panel D. Fractional excretion of urea (FEUr). AKIN: Acute
Kidney Injury Network.
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predominantly medical ICUs [10]. Interestingly, baseSCr
was significantly lower in no-AKI patients, a finding also
present in a study by Schinstock et al. [36]. This was not
the focus of our study, but it could be that patients who
developed AKI had lower basal glomerular filtration rate,
albeit still in the normal range.
Our study has some limitations. It was completed in a
single center, with a heterogeneous population of critic-
ally ill patients, so the reason for AKI development may
be quite variable, and imprecision is expected regarding
the moment that the kidneys were first injured. Besides
that, only patients with an indwelling urinary catheter at
admission were included which can introduce a bias in
the analysis. We believe that we have selected the most
critically ill patients and, therefore, the patients more
likely to develop AKI during ICU stay. On the other
hand, a heterogeneous population increases the chance
that our results can also be found in other general ICUs.
We decided to use only creatinine-based AKIN criteria
which certainly excluded some AKI diagnosis due only
to oliguria. Although a limitation, this increases the chance
that our results may be useful for patients without an in-
dwelling urinary catheter, such as patients in the wards,
where urinary flow is usually not available. The high per-
centage of AKI diagnosis at admission prevented us from
better exploring the possible role of some of the param-
eters studied in early AKI diagnosis since only a few
patients had data of D-2 and D-1 available for analysis.
Diuretics are always a confounding factor in urinary
biochemistry, but we demonstrated similar results in
patients that have or have not used diuretics during the
observation period (Additional file 1: Figures S1 and
Additional file 2: Figure S2). In addition, lower NaU
values in the early phase of AKI could not be attributed
to diuretic use since diuretics usually increase NaU
values, both in transient and persistent AKI [8]. A low
NaU value, even with diuretic use, is probably a marker
of AKI development.
Conclusions
The early phase of AKI development in critically ill pa-
tients is usually characterized by decreased values of
NaU, ClU and serum albumin as well as increased values
of SIG, phosphate and SIDu. Some of these alterations
may begin to occur earlier than creatinine elevation.
Transient and persistent AKI have similar alterations in
these blood and urinary physicochemical parameters,
differing only in their duration and severity. The degree
of alterations in these parameters is also associated with
the AKIN stage progression. Hence, sequential physico-
chemical analysis of blood and urine should be better
explored in future studies in order to define the utility of
these parameters as additional tools in AKI diagnosis
and management.
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